J.T. Coyle. Glutamate and schizophrenia: beyond the dopamine hypothesis. „Cellular and Molecular Neurobiology”. 26 (4-6), s. 365-384, 2006. DOI: 10.1007/s10571-006-9062-8. PMID: 16773445.
S.R. Veerman, P.F. Schulte, L. de Haan. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. „Pharmacopsychiatry”. 47 (4-5), s. 121-130, 2014. DOI: 10.1055/s-0034-1383657. PMID: 25002292.
D.C. Javitt, S.R. Zukin. Recent advances in the phencyclidine model of schizophrenia. „American Journal of Psychiatry”. 148 (10), s. 1301-1308, 1991. DOI: 10.1176/ajp.148.10.1301. PMID: 1654746.
J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman i inni. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. „Archives of General Psychiatry”. 51 (3), s. 199-214, 1994. DOI: 10.1001/archpsyc.1994.03950030035004. PMID: 8122957.
R. Omdal, K. Brokstad, K. Waterloo, W. Koldingsnes i inni. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. „European Journal of Neurology”. 12 (5), s. 392–398, 2005. DOI: 10.1111/j.1468-1331.2004.00976.x. PMID: 15804272.
K.P. Wandinger, S. Saschenbrecker, W. Stoecker, J. Dalmau. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. „J Neuroimmunol”. 231 (1-2), s. 86-91, 2011. DOI: 10.1016/j.jneuroim.2010.09.012. PMID: 20951441.
A. Marsman, M.P. van den Heuvel, D.W. Klomp, R.S. Kahn i inni. Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies. „Schizophrenia Bulletin”. 39 (1), s. 120-129, 2013. DOI: 10.1093/schbul/sbr069. PMID: 21746807.
A. Takata, Y. Iwayama, Y. Fukuo, M. Ikeda i inni. A population-specific uncommon variant in GRIN3A associated with schizophrenia. „Biological Psychiatry”. 73 (6), s. 532-539, 2013. DOI: 10.1016/j.biopsych.2012.10.024. PMID: 23237318.
G. Tsai, P. Yang, L.C. Chung, N. Lange i inni. D-serine added to antipsychotics for the treatment of schizophrenia. „Biol Psychiatry”. 44 (11), s. 1081-1089, 1998. DOI: 10.1016/S0006-3223(98)00279-0. PMID: 9836012.
S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe i inni. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. „Nature Medicine”. 13 (9), s. 1102–1107, 2007. DOI: 10.1038/nm1632. PMID: 17767166.
D.C. Goff, J.S. Lamberti, A.C. Leon, M.F. Green i inni. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. „Neuropsychopharmacology”. 33 (3), s. 465–472, 2008. DOI: 10.1038/sj.npp.1301444. PMID: 17487227.
T. Kishi, N. Iwata. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. „J Psychiatr Res”. 47 (9), s. 1143-1149, 2013. DOI: 10.1016/j.jpsychires.2013.04.013. PMID: 23692933.
B. Moghaddam, D. Javitt. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. „Neuropsychopharmacology”. 37 (1), s. 4–15, 2012. DOI: 10.1038/npp.2011.181. PMID: 21956446.
nih.gov
ncbi.nlm.nih.gov
J.T. Coyle. Glutamate and schizophrenia: beyond the dopamine hypothesis. „Cellular and Molecular Neurobiology”. 26 (4-6), s. 365-384, 2006. DOI: 10.1007/s10571-006-9062-8. PMID: 16773445.
S.R. Veerman, P.F. Schulte, L. de Haan. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. „Pharmacopsychiatry”. 47 (4-5), s. 121-130, 2014. DOI: 10.1055/s-0034-1383657. PMID: 25002292.
D.C. Javitt, S.R. Zukin. Recent advances in the phencyclidine model of schizophrenia. „American Journal of Psychiatry”. 148 (10), s. 1301-1308, 1991. DOI: 10.1176/ajp.148.10.1301. PMID: 1654746.
J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman i inni. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. „Archives of General Psychiatry”. 51 (3), s. 199-214, 1994. DOI: 10.1001/archpsyc.1994.03950030035004. PMID: 8122957.
R. Omdal, K. Brokstad, K. Waterloo, W. Koldingsnes i inni. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. „European Journal of Neurology”. 12 (5), s. 392–398, 2005. DOI: 10.1111/j.1468-1331.2004.00976.x. PMID: 15804272.
K.P. Wandinger, S. Saschenbrecker, W. Stoecker, J. Dalmau. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. „J Neuroimmunol”. 231 (1-2), s. 86-91, 2011. DOI: 10.1016/j.jneuroim.2010.09.012. PMID: 20951441.
A. Marsman, M.P. van den Heuvel, D.W. Klomp, R.S. Kahn i inni. Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies. „Schizophrenia Bulletin”. 39 (1), s. 120-129, 2013. DOI: 10.1093/schbul/sbr069. PMID: 21746807.
A. Takata, Y. Iwayama, Y. Fukuo, M. Ikeda i inni. A population-specific uncommon variant in GRIN3A associated with schizophrenia. „Biological Psychiatry”. 73 (6), s. 532-539, 2013. DOI: 10.1016/j.biopsych.2012.10.024. PMID: 23237318.
G. Tsai, P. Yang, L.C. Chung, N. Lange i inni. D-serine added to antipsychotics for the treatment of schizophrenia. „Biol Psychiatry”. 44 (11), s. 1081-1089, 1998. DOI: 10.1016/S0006-3223(98)00279-0. PMID: 9836012.
D.C. Javitt. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. „Current Opinion in Drug Discovery & Dvelopment”. 12 (4), s. 468-478, 2009. PMID: 19562643.
L.E. Chavez-Noriega, H. Schaffhauser, U.C. Campbell. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. „Curr Drug Targets CNS Neurol Disord”. 1 (3), s. 261-281, 2002. PMID: 12769619.
S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe i inni. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. „Nature Medicine”. 13 (9), s. 1102–1107, 2007. DOI: 10.1038/nm1632. PMID: 17767166.
D.C. Goff, J.S. Lamberti, A.C. Leon, M.F. Green i inni. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. „Neuropsychopharmacology”. 33 (3), s. 465–472, 2008. DOI: 10.1038/sj.npp.1301444. PMID: 17487227.
T. Kishi, N. Iwata. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. „J Psychiatr Res”. 47 (9), s. 1143-1149, 2013. DOI: 10.1016/j.jpsychires.2013.04.013. PMID: 23692933.
J.S. Kim, H.H. Kornhuber, W. Schmid-Burgk, B. Holzmüller. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. „Neuroscience Letters”. 20 (3), s. 379-382, 1980. PMID: 6108541.
B. Moghaddam, D. Javitt. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. „Neuropsychopharmacology”. 37 (1), s. 4–15, 2012. DOI: 10.1038/npp.2011.181. PMID: 21956446.
